Prenatal Diagnostics Market By Test Type (Invasive, Non- invasive (Bambni Test, Harmony, informSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, Verifi, VisibiliT, others) & Others), By Method (Blood or Saliva, Urine, Ultrasound, Amniocentesis, Chronic villus sampling, Percutaneous umbilical Sampling), By Application (Microdeletions Symptoms, Trisomy, Others), By End Use (Hospitals, Commercial or Private Laboratories, Public Health Laboratories & Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027
Prenatal Diagnostics Market Overview
Prenatal Diagnostics Market Size is estimated to reach $7.9 billion by 2027 and it is poised to grow at a CAGR of 12.4% over the forecast period of 2022-2027. Prenatal diagnosis is a way to find abnormalities of the child before its birth in the fetus stage. Prenatal diagnostics is in demand in the market owing to the rise in maternal age, miscarriage, a complication in pregnancy and the risk of chromosomal abnormalities which is helping to grow the market. As per the March of dimes organization about 1 in 150 babies are born with a chromosomal abnormality and as maternal age increases there is an increased chance of chromosomal abnormalities. For instance at age of 35 it is 1 in 192 and at 40 years age it increases up to 1 in 99. To diagnose this type of case, the prenatal diagnostic test is performed including non-invasive screening for detection of abnormalities and invasive procedures for diagnosis and treatment. This technique is used to identify hereditary diseases such as Down’s syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, genetic diseases, chromosome abnormalities, neural tube defects, congenital heart conditions and other conditions. There are various types of tests developed to identify such conditions like Bambni Test, Harmony, InformSeq, MaterniT21 PLUS, Non-invasive fetal Trisomy Test (NIFTY), Panorama, PrenaTest, Verifi, VisibiliT and it is categorized as the first trimester, second trimester and third-trimester screening and diagnostic tests. The test is scheduled according to the days of pregnancy from nine weeks to thirteen weeks and from fourteen to eighteen weeks. According to FDA report in April 2022, only Non-invasive prenatal screening/testing is not sufficient to make the decision about pregnancy as it has chances to show false results. So experts suggest additional testing by taking samples such as amniocentesis, chorionic villus sampling, Fetal blood sampling and Amnion Fluid to get confirm results by sequencing of genes. Availability of advanced technology, healthcare infrastructure with advancements in bioinformatics and increasing government support like reimbursement policies favor the market and is anticipated to grow Prenatal Diagnostics Industry over the forecast period 2022-2027.
Prenatal Diagnostics Market Report Coverage
The report: “Prenatal Diagnostics Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments in the Prenatal Diagnostics Market.
- Geographically, North America held a dominant market share in the year 2021, owing to advanced health infrastructure in countries like the United States and Canada.
- The Prenatal Diagnostics Market size is predicted to increase owing to the increasing number of the adolescent population, currently 1.3 billion adolescents in the world in 2022 as per UNICEF. However, the high cost of equipment may limit market growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Prenatal Diagnostics Market Report.
Prenatal Diagnostics Market: Market Share (%) by Region, 2021
For More Details on This Report - Request for Sample
Prenatal Diagnostics Market Segmentation Analysis- By Test Type
Prenatal Diagnostics Market based on test type can be further segmented into Invasive, Non- invasive (Bambni Test, Harmony, informSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, Verifi, VisibiliT, others) and Others. The non-invasive segment held a dominant Prenatal Diagnostics market share in the year 2021, attributed to the procedure's non-invasive nature, higher accuracy and short duration. The non-invasive test includes Bambni Test, Harmony, informSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, Verifi, VisibiliT and others. Among them, MaterniT21 PLUS is the most popular owing to its ability to screen certain syndromes called trisomies, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) and it is 100% safe and 99% accurate. Such availability of various advanced non-invasive tests propels Prenatal Diagnostics Industry.
However, the Invasive test is estimated to grow with the fastest CAGR of 13.2% over the forecast period. Owing to the latest guidelines updated by FDA in April 2022, it states that non-invasive tests are not sufficient to make a decision about the pregnancy and they suggest an invasive procedure for confirmation like a testing sample of amniocentesis, chorionic villus sampling, Fetal blood sampling and Amnion Fluid. These tests help to boost the invasive prenatal diagnostics industry over the forecast period 2022-2027.
Prenatal Diagnostics Market Segmentation Analysis- By Method
Prenatal Diagnostics Market based on method can be further segmented into Blood or Saliva, Urine, Ultrasound, Amniocentesis, Chronic villus sampling, Percutaneous umbilical Sampling and Others. The Ultrasound segment held a dominant Prenatal Diagnostics market share in the year 2021. This is owing to the rising preference for ultrasound, non- invasiveness, safety assurance and the high-end development of ultrasound technology which is able to develop 3D and 4D images help to grow this segment.
However, Chronic villus sampling is estimated to grow with the fastest CAGR of 13.5% over the forecast period 2022-2027. Owing to assured results related to a birth defect, genetic diseases and other problems during pregnancy. It is usually done between the 10th to 12th weeks of pregnancy. CVS is estimated to give a definitive result in 99 out of every 100 women having the test as per National Health Service. Such advantages of CVS are helping to grow the market over the forecast period 2022-2027.
Prenatal Diagnostics Market Segmentation Analysis- By Geography
The Prenatal Diagnostics Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant Prenatal Diagnostics market share of 35% in the year 2021. The age of a woman to give birth to her child is 30 or above in America as per OECD. As age increases there is a high chance of getting abnormalities in babies as per the National Health of Medicines, at the maternal age of 20 the risk of trisomy is 1: 1480 and the risk of other chromosomal abnormality is 1:525 which is high increases at age 45, risk of trisomy is 1:35 and another chromosomal abnormality is 1:18. As the age increases, there is a high risk of pregnancy difficulty which support the Prenatal Diagnostics Market size. Also various governments take-up initiatives to assist pregnant women and secure children are also propelling the market growth. As per The American College of Obstetricians and Gynaecologists, approximately 80% of insured patients in the US are covered for NIPT regardless of risk and nearly 100% are covered in a high-risk pregnancy. These factors fuel market growth.
Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. Owing to more than 59.76% of the world population living in this region and 60% of the world adult population between 25 to 35 years lives in Asia as per UN world regional overview and world data statistics. This number reveals the high number of fertile populations living in Asia which widen the scope for the Prenatal Diagnostic Market over the forecast period.
Prenatal Diagnostics Market Drivers
Rising Incidence of Genetic Disabilities and Pregnancy Complications Drives the Market Growth.
Genetic diseases such as downy syndrome, Edwards syndrome, Patau syndrome, Turner syndrome and other types of chromosomal abnormalities are increasing. According to nature, more than 7.9 million infants (which is 6% of worldwide births) are born with serious birth defects. This is owing to the increase in late marriage preference by women, hectic lifestyles and unhealthy food consumption. Many more research studies proved that taking the late chance of having a baby more than 30 years, the chromosomal abnormalities and complications in delivery will increase. Also, every parent wants their child safe from any type of abnormality and preferred prenatal diagnosis help to drive Prenatal Diagnostic Market.
Advanced Technology for Prenatal Testing Aid Market Growth.
Diagnosis of Prenatal is very difficult without the use of advanced technology, non- invasive method is mostly preferred by customers to avoid any type of surgery, or cut on or inside the body. However, invasive procedures like amniocentesis, chorionic villus sampling, Fetal blood sampling and Amnion Fluid are also preferred for accurate results enhancing the Prenatal Diagnostics market size. Also, rapid advancement and high-performance molecular diagnostic tools give accurate results. The Discovery of cell-free fetal DNA in maternal plasma enables accurate diagnosis of chromosomal disorders. Bambni Test, Harmony, informSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, Verifi, VisibiliT and other tests are also available in the market for prenatal testing. Such genetic testing for pregnancy costs can go from $100 to $1000 in the U.S. Such use of advanced technology for accurate results fuels the Prenatal Testing Market.
Prenatal Diagnostics Market Challenges
High Cost of Technology Used for Detection Stymie Market Growth.
The advanced technology used for the detection of chromosomal abnormalities is very expensive and is not affordable to people with middle-low and low incomes. Also, this treatment does not yet reach many developing and poor countries owing to a lack of good healthcare infrastructure, capable workforce. And skilled persons also lack of investment and low expenditure on healthcare limit the market for prenatal diagnosis in such countries. In an underdeveloped and poor country, it is very luxurious and out of pocket to take such treatment and most of the population is away from such kind of treatment due to the high-cost burden and nominal income. According to World Health Organisation, half the population around the world lacks essential health services and every year 100 million are pushed into extreme poverty owing to the out-of-pocket health burden which hampers market growth over the forecast period 2022-2027.
Prenatal Diagnostics Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Prenatal Diagnostics Market. The top 10- Prenatal Diagnostics Market companies are-
- Quest Diagnostics
- GeneDx, Inc.
- Natera, Inc.
- Illumina, Inc.
- Ravgen Inc.
- Prenatal Paternities Inc.
- Ariosa Diagnostics, Inc.
- Eurofins NTD Inc.
- Counsyl, Inc.
- In January 2022, Sema4 – AI-driven genomics and clinical data intelligence platform acquired GeneDx. Which help Sema4 with leadership GeneDx in rare disease diagnostic and exome sequencing with more than 300,000 clinical exomes and 2.1million expertly annotated phenotype which is to find 12 million de-identified clinical records of Centrellis of sema4.
- In January 2022, Natera, a leader in personalized genetic testing and diagnostics announced expansion into the early cancer detection market. With aims to strengthen its roots in (Early Cancer Detection) market and Molecular Residual Diseases (MRD).
- In June 2020, Quest Diagnostics- a leading provider of diagnostics information services acquired Mid America Clinical Laboratories in India with the aim to design optimized delivery with high-quality and innovative diagnostic laboratory service in Indiana. With this acquisition about 30 hospital labs come under the company network.
Report Code: HCR 0081
Report Code: HCR 42294
Report Code: HCR 0652
For more Lifesciences and Healthcare Market reports, please click here